The first trial is SOLAR-STAGE: a Phase 3, multicenter, open-label study to evaluate the diagnostic performance of copper Cu 64 PSMA I&T PET/CT in staging of men with newly diagnosed unfavorable ...

The proposed acquisition of Eczacıbaşı-Monrol will: Build on existing partnership in Lu-177 creating a leading manufacturer of the isotope Add 12 PET sites to Curium’s existing network in ...

Element 117 was named tennessine because of the participation of Oak Ridge National Laboratory, Vanderbilt University and the ...

This is the second part of a three-part series written by Carolyn Krause. Many of the elements were synthesized using an Oak ...

For a business news site based in the regions it raised a fundamental concern over the impact artificial intelligence (AI) ...

But the conversation also covered the impact of AI on work which was considered from various perspectives. Carolyn Hicks said ...

ST. LOUIS, April 23, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has successfully enrolled and scanned patients in its SOLAR clinical trials ...

About Curium Curium is a world leader in nuclear medicine. We develop, manufacture, and distribute world-class radiopharmaceutical products to help patients around the globe.

Try refreshing your browser, or tap here to see other videos from our team. Curium Plans to Significantly Expand Lutetium-177 Capacity and Pet Footprint With Agreement to Acquire Eczacibaşi-Monrol ...